English
中文PB-1902 the only oral opioid receptor antagonist for the treatment of opioid-induced constipation (OIC)
- 产品概览
- 作用机理
- 产品特点与优势
- 研究进展
-
PB-1902 is the only oral opioid receptor antagonist for the treatment of opioid-induced constipation (OIC) under clinical trials in China. It relieves the opioid-induced bowel dysfunction without compromising the analgesic effect, making it an ideal option for the treatment of OIC.
PB-1902 is currently undergoing the phase I clinical trial in China. It is expected to become the first oral opioid receptor antagonist in China, fulfilling the unmet medical need of the target population.
-
阿片类镇痛药物通过结合中枢神经系统的μ受体，缓解病患中、重度疼痛。同时，阿片类药物会与胃肠道内μ受体结合，抑制胃肠蠕动，减少胆汁和胰腺的分泌，从而引起便秘。PB-1902作为μ受体拮抗剂可以有效结合肠道μ受体，从而竞争性减少阿片类药物与肠道内受体结合，缓解长期使用此类药物引起的便秘；同时， PB-1902穿越血脑屏障能力弱，不影响阿片类药物在中枢神经系统与μ受体的结合；从而达到治疗便秘但又不影响阿片类药物的镇痛效果。
-
（1） 口服剂型，方便患者使用
（2） 有效改善便秘，不易拮抗阿片类镇痛作用
-
PB-1902正在中国开展I期临床研究。